文献速递临床试验与 GCP流行病学与生物统计

在咨询基础上加用伐尼克兰对非裔美国每日吸烟者戒烟效果的影响:Kick It at Swope IV 随机临床试验

Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers: The Kick It at Swope IV Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

该随机双盲安慰剂对照试验在堪萨斯城联邦合格健康中心纳入500名非裔美国每日吸烟成人,比较伐尼克兰(1 mg每日两次,n=300)与安慰剂(n=200)联合6次咨询的戒烟效果,主要终点为第26周经唾液可替宁验证的7天时点戒烟率。伐尼克兰组第26周戒烟率15.7% vs 安慰剂组6.5%(OR 2.7,95%CI 1.4-5.1,P=0.002),差异有统计学意义;结论支持在咨询基础上加用伐尼克兰用于该人群的烟草使用治疗。

要点

  • 第26周经唾液可替宁验证的7天时点戒烟率:伐尼克兰组15.7% vs 安慰剂组6.5%(OR 2.7,95%CI 1.4-5.1,P=0.002)。
  • 第12周戒烟率:伐尼克兰组18.7% vs 安慰剂组7.0%(OR 3.0,95%CI 1.7-5.6,P<0.001)。
  • 轻度吸烟者第12周戒烟率:伐尼克兰组22.1% vs 安慰剂组8.5%(OR 3.0,95%CI 1.4-6.7,P=0.004);中重度吸烟者:伐尼克兰组15.1% vs 安慰剂组5.3%(OR 3.1,95%CI 1.1-8.6,P=0.02)。

核心结论

  • 在非裔美国每日吸烟成人中,与咨询加安慰剂相比,咨询加伐尼克兰在第26周7天时点戒烟率上取得有统计学意义的改善。
  • 研究结果支持在非裔美国每日吸烟成人的烟草使用治疗中,在咨询基础上加用伐尼克兰。

研究设计与样本

  • Kick It at Swope IV(KIS-IV)试验为随机、双盲、安慰剂对照临床试验,在堪萨斯城一家联邦合格健康中心开展。
  • 2015年6月至2017年12月共纳入500名各吸烟水平的非裔美国每日吸烟成人,最终随访于2018年6月完成。
  • 参与者接受6次文化相关的个体化咨询,并按3:2比例随机接受伐尼克兰(1 mg每日两次,n=300)或安慰剂(n=200)治疗12周;随机化按性别和吸烟水平(每日1-10支[轻度吸烟者]或>10支[中重度吸烟者])分层。

主要发现

  • 将失访者视为吸烟者,伐尼克兰组第26周戒烟率15.7% vs 安慰剂组6.5%(差值9.2%,95%CI 3.8%-14.5%;OR 2.7,95%CI 1.4-5.1;P=0.002)。
  • 治疗第12周结束时,伐尼克兰组戒烟率18.7% vs 安慰剂组7.0%(差值11.7%,95%CI 6.0%-17.7%;OR 3.0,95%CI 1.7-5.6;P<0.001)。
  • 轻度吸烟者第12周戒烟率:伐尼克兰组22.1% vs 安慰剂组8.5%(差值13.6%,95%CI 5.2%-22.0%;OR 3.0,95%CI 1.4-6.7;P=0.004)。
  • 中重度吸烟者第12周戒烟率:伐尼克兰组15.1% vs 安慰剂组5.3%(差值9.8%,95%CI 2.4%-17.2%;OR 3.1,95%CI 1.1-8.6;P=0.02);吸烟水平与治疗的交互作用无统计学意义(P=0.96)。
  • 药物不良事件在两组间总体相当,恶心在伐尼克兰组报告更频繁(293例中163例[55.6%]) vs 安慰剂组(196例中90例[45.9%])。

关键数值与推荐

  • 主要终点为第26周经唾液可替宁验证的7天时点戒烟率。
  • 次要终点为第12周7天时点戒烟率,并对轻度吸烟者(每日1-10支)和中重度吸烟者(每日>10支)进行亚组分析。
  • 500名随机化并完成基线访视的参与者中,441名(88%)完成试验;参与者平均年龄52岁,262名(52%)为女性,260名(52%)为轻度吸烟者,429名(86%)使用薄荷醇。

临床怎么用

  • 研究结果支持在非裔美国每日吸烟成人的烟草使用治疗中,在咨询基础上加用伐尼克兰。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: African American smokers have among the highest rates of tobacco-attributable morbidity and mortality in the US, and effective treatment is needed for all smoking levels. OBJECTIVES: To evaluate the efficacy of varenicline vs placebo among African American adults who are light, moderate, and heavy daily smokers. DESIGN, SETTING, AND PARTICIPANTS: The Kick It at Swope IV (KIS-IV) trial was a randomized, double-blind, placebo-controlled clinical trial conducted at a federally qualified health center in Kansas City. A total of 500 African American adults who were daily smokers of all smoking levels were enrolled from June 2015 to December 2017; final follow-up was completed in June 2018. INTERVENTIONS: Participants were provided 6 sessions of culturally relevant individualized counseling and were randomized (in a 3:2 ratio) to receive varenicline (1 mg twice daily; n = 300) or placebo (n = 200) for 12 weeks. Randomization was stratified by sex and smoking level (1-10 cigarettes/d [light smokers] or >10 cigarettes/d [moderate to heavy smokers]). MAIN OUTCOMES AND MEASURES: The primary outcome was salivary cotinine-verified 7-day point prevalence smoking abstinence at week 26. The secondary outcome was 7-day point prevalence smoking abstinence at week 12, with subgroup analyses for light smokers (1-10 cigarettes/d) and moderate to heavy smokers (>10 cigarettes/d). RESULTS: Among 500 participants who were randomized and completed the baseline visit (mean age, 52 years; 262 [52%] women; 260 [52%] light smokers; 429 [86%] menthol users), 441 (88%) completed the trial. Treating those lost to follow-up as smokers, participants receiving varenicline were significantly more likely than those receiving placebo to be abstinent at week 26 (15.7% vs 6.5%; difference, 9.2% [95% CI, 3.8%-14.5%]; odds ratio [OR], 2.7 [95% CI, 1.4-5.1]; P = .002). The varenicline group also demonstrated greater abstinence than the placebo group at the end of treatment week 12 (18.7% vs 7.0%; difference, 11.7% [95% CI, 6.0%-17.7%]; OR, 3.0 [95% CI, 1.7-5.6]; P < .001). Smoking abstinence at week 12 was significantly greater for individuals receiving varenicline compared with placebo among light smokers (22.1% vs 8.5%; difference, 13.6% [95% CI, 5.2%-22.0%]; OR, 3.0 [95% CI, 1.4-6.7]; P = .004) and among moderate to heavy smokers (15.1% vs 5.3%; difference, 9.8% [95% CI, 2.4%-17.2%]; OR, 3.1 [95% CI, 1.1-8.6]; P = .02), with no significant smoking level × treatment interaction (P = .96). Medication adverse events were generally comparable between treatment groups, with nausea reported more frequently in the varenicline group (163 of 293 [55.6%]) than the placebo group (90 of 196 [45.9%]). CONCLUSIONS AND RELEVANCE: Among African American adults who are daily smokers, varenicline added to counseling resulted in a statistically significant improvement in the rates of 7-day point prevalence smoking abstinence at week 26 compared with counseling and placebo. The findings support the use of varenicline in addition to counseling for tobacco use treatment among African American adults who are daily smokers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02360631.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Cox LS, Nollen NL, Mayo MS, et al. Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers: The Kick It at Swope IV Randomized Clinical Trial. JAMA. 2022. PMID: 35699705. doi:10.1001/jama.2022.8274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。